Molecular Neurobiology
Copyright
9 1994 Humana Press Inc.
All rights of any nature whatsoever reserved.
ISSN0893-7648/94/8(2-3): 99-103/$5.00
A Novel Mechanism
of Phenotypic Heterogeneity Demonstrated
by the Effect of a Polymorphism
on a Pathogenic Mutation
in the PRNP (Prion Protein Gene)
Robert B. Petersen, ~,"Lev G. Goldfarb, 2 Massimo Tabaton,
Paul Brown, 2 Lucia Monari, i Pietro Cortelli, 3
Pasquale Montagna, 3 Lucila Autilio-Gambetti, ~
D. Carleton Gajdusek, 2 Elio Lugaresi, 3 a n d Pierluigi Gambetti ~
llnstitute of Pathology, Case Western Reserve University, Cleveland, OH 44106;
2National Institutes of Health, Bethesda, MD 20892;
~Neurological Institute, University of Bologna, Bologna, Italy
Abstract
Fatal familial insomnia (FFI) is a subacute dementing illness originally described in 1986. The phenotypic
characteristics of this disease include progressive untreatable insomnia, dysautonomia, endocrine and motor
disorders, preferential hypometabolism in the thalamus as determined by PET scanning, and selective thalamic atrophy. These characteristics readily distinguish FFI from other previously described neurodegenerative
conditions. Recently, FFI was shown to be linked to a mutation in the prion protein gene (PRNP) at codon 178,
which results in the substitution of asparagine for aspartic acid. As such, FFI represents the most recent addition to the growing family of prion protein-related diseases. The mutation that results in FFI had previously
been linked to a subtype of familial Creutzfeld-Jakob disease (178Ash CJD). The genotypic basis for the difference between FFI and 178AsnCJD lies in a polymorphism at codon 129 of the mutant prion protein gene: 129Met
178Ash results in FFI, 129val 178Asn in CJD. The finding that the combination of a polymorphism and a single
pathogenic mutation result in two distinct conditions represents a significant advance in our understanding of
phenotypic variability.
Index Entries: Fatal familial insomnia; Creutzfeldt-Jakob disease; dementia; PRNP; mutation; polymorphism; phenotype; prion.
*Author to whom all correspondence and reprint requests should be addressed.
Molecular Neurobiology
99
Volume 8, 1994
100
Introduction
Fatal familial insomnia (FFI) was first described
in a large Italian kindred as a neurodegenerative
condition that presented with progressive insomnia, demonstrated by polysomnography and auton o m i c d y s f u n c t i o n (1). Pathologic e v a l u a t i o n
demonstrated severe neuronal loss in the anterior
and dorsomedial thalamic nuclei without spongiotic,
vascular, or inflammatory changes. In addition to
being the first example of a genetically linked condition that affected specific thalamic nuclei, FFI
underscored the importance of these nuclei in the
regulation of the sleep-wake cycle, as well as in
other autonomic functions.
Five additional cases of longer duration were
subsequently reported (2). In one of these cases,
there was focal spongiosis in the cerebral cortex, but
otherwise the pathology was identical to the original cases. The spongiform degeneration in this case
suggested that it might be a familial prion disease.
Protease-resistant prion protein (PrP) was detected,
and analysis of the PRNP revealed that there was a
mutation at codon 178 (3) that replaced the normal
aspartic acid with asparagine (178Ash). Following
this discovery, the 178 Asn mutation was found in
four additional FFI families (4,5). The cumulative
LOD score for 178 mutation in the five families is
6.5. Surprisingly, at the time that the genetic basis
of FFI was being uncovered, the genetic lesion in
one form of familial Creutzfeldt-Jakob was shown
to be an identical mutation at codon 178 (6).
Characterization
of FFI and 178Asn CJD
The revelation that FFI and 178 Ash CJD shared a
c o m m o n mutation necessitated a careful clinical
and pathologic review of the two conditions. FFI
presents clinically with progressive insomnia characterized by loss of slow wave and REM sleep,
which can be rigorously established by overnight
polysomnography (1). This type of formal documentation is critical since approx 30% of adults over
50 yr of age report some sleep disturbance (7). FFI
results in an inability to generate electrophysiological sleep patterns, not merely a reduction in sleep
(8). In one case of 178 Ash CJD tested by polysomnography, no sleep disturbance was detected (9
and M. Haltia and M. Partinen, personal communication). FFI also alters autonomic functions and circadian rhythms, while sparing mental function in
Molecular Neurobiology
Petersen et al.
the early stages of the disease. In contrast, patients
affected by CJD generally present with rapidly progressive dementia (10).
Pathologic examination allows further differentiation. FFI specifically affects the thalamus, and
only in cases of long duration is there focal involvement of the cerebral cortex (Fig. 1). In contrast,
178 Ash CJD demonstrates widespread spongiosis in
the cerebral cortex irrespective of disease duration,
and no specific thalamic degeneration (Fig. 1). Thus,
FFI and 178Ash CJD can be distinguished on both
clinical and pathologic grounds, leaving us with the
quandary as to how a single mutation can result in
these two conditions.
Codon 129 Polymorphism in PRNP
There is a well-documented polymorphism in
PRNP at codon 129 that codes for either methionine
or valine (11). Although the valine allele is not part i c u l a r l y rare, a r o u n d 38%, C o l l i n g e and his
coworkers have shown that within the sporadic and
iatrogenic cases of CJD, there is a statistically
skewed distribution of alleles (12). In their study,
although 51% of the normal population was heterozygous at codon 129, only 11% of the sporadic
cases of CJD were heterozygous. Of the homozygous
cases in the normal population, 22% were valine
and 78% were methionine. On the basis of these
data, we reasoned that the polymorphism at codon
129 might have an effect on the expression of the
178 mutation.
Analysis of 15 FFI- and 15 178 Ash CJD-affected
subjects showed a remarkably skewed distribution
at codon 129 (9); most notably in FFI there were no
subjects homozygous for Val whereas in 178 ash CJD,
there were no subjects homozygous for Met (Fig. 2).
However, these data did not provide a genetic
explanation for the difference b e t w e e n FFI and
178AshCJD, since there were heterozygous individuals in both instances. Consequently, we examined
codon 129 on the mutated allele, and discovered that
in all cases FFI was linked to methionine and that
178 Ash CJD was linked to valine at codon 129.
Thus, the polymorphism at codon 129 in conjunction with the mutation at codon 178 results in two
different conditions.
The question remaining was whether codon 129
on the normal allele had any effect on the disease. It
had been suggested previously that heterozygosity
at codon 129 had a "protective" effect from iatrogenic transmission of CJD and resulted in a prolonged disease course in sporadic CJD (12). The
Volume 8, 1994
101
Mechanism of Phenotypic Heterogeneity
FFI
178AsnCJD
Fig. 1. Distribution of lesions in FFI and 178AshCJD. Note that in FFI, the thalamus is most severely affected,
but the lesions (in the thalamus) do not include spongiform degeneration. In contrast, the lesions associated
with 178Ash CJD are prominent in the cerebral cortex and are characterized by spongiform degeneration. (A =
neuronal loss and gliosis; 9 = spongiform degeneration)
Met/Met
MetlVal
Val/Val
Normal
37%
51%
12O/o
FFI
80%
20%
0%
CJD
0%
60%
40~
Discussion
Taken in sum, our data show that the codon 129
p o l y m o r p h i s m operates to modify the disease process both qualitatively and quantitatively in association with the codon 178 mutation (Fig. 3). C o d o n
Met
62%
90%
30%
129 acts as a binary switch on the m u t a n t allele
Val
38%
10%
70%
r e s u l t i n g in t w o clinically a n d p a t h o l o g i c a l l y
Fig. 2. Prevalence of the Met/Val polymorphism at distinct entities. 129Met\178 Ash causes FFI, w h i c h
largely
codon 129 of PRNP in a normal Caucasian population is characterized by insomnia and a pathology
Val ~
Asn
confined
to
the
thalamus,
whereas
129
\178
and in patients with FFI or 178 Asn CJD (9,12). The
upper part of the figure shows the distribution of causes 178 Ash CJD, which lacks the FFI sleep disturgenotypes in normal, FFI, and 178AshCJD populations. bance and possesses widespread cortical pathology.
The lower part of the figure shows the distribution of Phrased in another wa)~ the 129 p o l y m o r p h i s m on
the m u t a n t allele appears to dictate the disease
alleles in the three populations.
topography, which in turn is reflected in the clinical
presentation. On the normal allele, codon 129 acts
disease duration in heterozygous FFI patients was as a modulator of the disease severity. Individuals
26 + 10 mo, whereas the h o m o z y g o u s FFI patients h e t e r o z y g o u s at c o d o n 129 are p a r t i a l l y "prohad a disease course of 12 + 4 mo (p < 0.002). Simi- tected," with a prolonged disease course compared
larly, in 178 Ash CJD patients, the disease course in to homozygotes in both FFI and 178 Ash CJD and a
the h e t e r o z y g o t e s w a s 27 + 14 mo, a n d in the delayed onset of disease in 178 A~n CJD. Thus, the
homozygotes, 14 + 4 mo (p < 0.05). In addition to 129 p o l y m o r p h i s m on the normal allele dictates the
the difference in disease duration, the onset of dis- disease severity.
ease was markedly earlier in 178 Ash CJD homozyOne of the inherent difficulties in genetic analygotes (39 + 8 yr vs 49 + 4 yr; p < 0.01).
sis of rare diseases is that the sample sizes are small.
Molecular Neurobiology
Volume 8. 1994
102
Petersen et al.
Fatal FamilialInsomnia (FFI)
178 Asn CJD Subtype (CJD)
ModifiesDisease ~ , ~
M e t h i o n ~
Valine
178Asn Mutant
(I
178Asp Normal
q
Cdoo1~n129
~L.
%,[~eles
1)---~-
FFI (ShorterDuration-EarlierOnset) CJD
Fig. 3. Effect of the codon 129 polymorphism on expression of the 178ash mutation.
As a result, it is possible that a mutation or polymorphism linked to a disease may actually be just a
marker for the disease-causing locus rather than the
cause or modifier of the disease. We have considered this possibility of the association of the codon
129 polymorphism with FFI and 178Ash CJD. Two
recent cases have clarified this issue.
In the first case, described by Bosque et al. (13),
the proband presented with low-grade fever, night
sweats, and a rash. These symptoms were followed
by claustrophobia and insomnia. Eighteen months
after the onset of symptoms, PET scanning showed
reduction of activity in the thalamus and medial
frontal lobes. The subject died 25 mo after onset of
symptoms. A collaborative review of the neuropathology in this case (C. L. Vnencak-Jones, M.
Johnson, and P. Gambetti, personal communication)
revealed that the lesions were similar to those in FFI
of long duration. In accord with this diagnosis, most
of the other affected relatives are reported to have
suffered from insomnia (13). Analysis of the PRNP
in this family demonstrated the codon 178 Ash mutation on a codon 129 methionine allele, as one would
expect, but in addition there was a 24-base deletion
resulting in the juxtaposition of codons 82 and 91.
As p r e d i c t e d from the relatively long disease
course, the proband was found to be heterozygous at codon 129 (C. L. Vnencak-Jones, personal
communication). The 24-bp deletion present in
this case is a rare polymorphism, estimated at 1-3%
(14,15), that is, in and of itself, apparently not pathogenic (15).
A second case with a genotype apparently identical to that described by Bosque has recently been
identified (A. Reder, R. Roos, and J. P. Spire, per-
Molecular Neurobiology
sonal communication). In this case, the diagnosis of
FFI was made during the life of the patient based
on polysomnography. The histopathology was also
consistent with the diagnosis of FFI. Thus, the two
families with a 129Met, 178Ash, and 24-bp deletion on
the same allele manifest a condition that is more
similar to FFI than to 178 Ash CJD. Since these families are not related to the previous FFI kindred, we
conclude that the 129 polymorphism provides the
switch resulting in FFI or 178 Ash CJD, rather than
acting as marker for another locus.
This represents the first observation that a common polymorphism can modify the expression of a
pathogenic mutation. This novel mechanism may
help explain phenotypic heterogeneity that has
been observed in other familial diseases.
Acknowledgments
We thank all the physicians and families whose
cooperation was, and continues to be, vital to these
studies. In addition, Mark Cohen for critical reading
of the manuscript and Sandra Richardson for expert
technical assistance. This work was supported by
NIA AG-08992-02, NIH NIA 1R01 AGNS08155-02,
NATO 910672, and the Britton Fund.
References
1. Lugaresi E., Medori R., Montagna P., et al. (1986) N.
Engl. J. Med. 315, 997-1003.
2. Manetto V., Medori R., Cortelli P., et al. (1992)
Neurology 42, 312-319.
3. Medori R., Tritschler H. J., LeBlanc A., et al. (1992) N.
Engl. J. Med. 326, 444-449.
Volume 8, 1994
Mechanism of Phenotypic Heterogeneity
4. Medori R., Montagna P., Tritschler H. J., et al. (1992)
Neurology 42, 669--670.
5. Petersen R. B., Tabaton M., Berg L., et al. (1992)
Neurology 42, 1859-1863.
6. Goldfarb L. G., Haltia M., Brown P., et al. (1991)
Lancet 337, 425.
7. Lugaresi E., Cirignotta F., Zucconi S., et al. (1983)
in Sleep~Wake Disorders: Natural History, Epidemiology
and Long-Term Evolution (Guilleminault C. and
Lugaresi E., eds.), Raven, New York, pp. 1-12.
8. Lugaresi E. (1992) Neurology 42 (Suppl. 6), 28-33.
9. Goldfarb L. G., Petersen R. B., Tabaton M., et al.
(1992) Science 258, 806-808.
Molecular Neurobiology
103
10. Brown P., Goldfarb L. G., Kovanen J., et al. (1992)
Ann. Neurol. 31, 282-285.
11. Goldfarb L. G., Brown P., Goldgaber D., et al. (1989)
Am. J. Hum. Genet. 45 (Suppl.), A189.
12. Palmer M. S., Dryden A. J., Hughes J. T., and Collinge
J. (1991) Nature 352, 340-342.
13. Bosque P. J., Vnencak-Jones C. L., Johnson M. D.,
Whitlock J. A., and McLean M. J. (1992) Neurology 42,
1864-1870.
14. Vnencak-Jones C. L. and Phillips III J. A. (1992) Am.
J. Hum. Genet. 50, 871-872.
15. Palmer M. S., Mahal S. P., Campbell T. A., et al. (1993)
Hum. Mol. Genet. 2, 541-544.
Volume 8, 1994